Search Results - "Giménez‐Arnau, A."

Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria by Kaplan, A. P., Giménez‐Arnau, A. M., Saini, S. S.

“…The monoclonal anti‐immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria…”
Get full text

The burden of chronic spontaneous urticaria is substantial: Real‐world evidence from ASSURE‐CSU by Maurer, M., Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez‐Arnau, A., Grattan, C., Hollis, K., Knulst, A., Lacour, J.‐P., Lynde, C., Marsland, A., McBride, D., Nakonechna, A., Ortiz de Frutos, J., Proctor, C., Sussman, G., Sweeney, C., Tian, H., Weller, K., Wolin, D., Balp, M.‐M.

“…Background Chronic spontaneous urticaria (CSU) can be debilitating, difficult to treat, and frustrating for patients and physicians. Real‐world evidence for…”
Get full text

Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from ASSURE‐CSU by Sussman, G., Abuzakouk, M., Bérard, F., Canonica, W., Oude Elberink, H., Giménez‐Arnau, A., Grattan, C., Hollis, K., Hunter, S., Knulst, A., Lacour, J.‐P., Lynde, C., Marsland, A., McBride, D., Maurer, M., Nakonechna, A., Ortiz de Frutos, J., Reynolds, M., Sweeney, C., Tian, H., Weller, K., Wolin, D., Balp, M.‐M.

“…Background ASSURE‐CSU revealed differences in physician and patient reporting of angioedema. This post hoc analysis was conducted to evaluate the actual rate…”
Get full text

Sensitive skin: A relevant syndrome, be aware by Wollenberg, A., Giménez‐Arnau, A.

“…Sensitive skin is clinically defined by characteristic sensory perceptions including tightness, abnormal stinging, burning, tingling, pain and pruritus. Facial…”
Get full text

EAACI/GA²LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria by Zuberbier, T, Asero, R, Bindslev-Jensen, C, Walter Canonica, G, Church, M.K, Giménez-Arnau, A, Grattan, C.E.H, Kapp, A, Merk, H.F, Rogala, B, Saini, S, Sánchez-Borges, M, Schmid-Grendelmeier, P, Schünemann, H, Staubach, P, Vena, G.A, Wedi, B, Maurer, M

“…This guideline, together with its sister guideline on the management of urticaria [Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK,…”
Get full text

Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement by Giménez‐Arnau, A., Curto‐Barredo, L., Nonell, L., Puigdecanet, E., Yelamos, J., Gimeno, R., Rüberg, S., Santamaria‐Babi, L., Pujol, R.M.

“…Background The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical characteristics, associated comorbidities, course of the…”
Get full text

Update on rupatadine in the management of allergic disorders by Mullol, J., Bousquet, J., Bachert, C., Canonica, G. W., Giménez‐Arnau, A., Kowalski, M. L., Simons, F. E. R., Maurer, M., Ryan, D., Scadding, G.

“…In a review of rupatadine published in 2008, the primary focus was on its role as an antihistamine, with a thorough evaluation of its pharmacology and…”
Get full text

Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria by de Montjoye, L, Darrigade, A S, Giménez-Arnau, A, Herman, A, Dumoutier, L, Baeck, M

“…Biomarkers of disease activity/severity and criteria of autoimmune chronic spontaneous urticaria (CSU) are still a matter of debate. To investigate possible…”
Get full text

The Chronic Urticaria Registry: rationale, methods and initial implementation by Weller, K., Giménez‐Arnau, A., Grattan, C., Asero, R., Mathelier‐Fusade, P., Bizjak, M., Hanna, M., Maurer, M.

“…Background Chronic urticaria (CU) is a common disease, characterized by the recurrent appearance of wheals, angioedema or both for more than 6 weeks. Its…”
Get full text

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria by Giménez-Arnau, A. M., Toubi, E., Marsland, A. M., Maurer, M.

“…This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is…”
Get full text

Management of urticaria: not too complicated, not too simple by Ferrer, M., Bartra, J., Giménez-Arnau, A., Jauregui, I., Labrador-Horrillo, M., Ortiz de Frutos, J., Silvestre, J. F., Sastre, J., Velasco, M., Valero, A.

“…Summary In spite of being an old disease and apparently easy to diagnose, chronic spontaneous urticaria (CSU) is still perceived as an uncontrollable and…”
Get full text

New‐onset and exacerbations of psoriasis after mRNA COVID‐19 vaccines: two sides of the same coin? by Pesqué, D., Lopez‐Trujillo, E., Marcantonio, O., Giménez‐Arnau, A.M., Pujol, R.M.

Get full text

The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg by Giménez-Arnau, A, Izquierdo, I, Maurer, M

“…According to the EAACI/GA(2)LEN/EDF guidelines for urticaria management, modern non-sedating H1-antihistamines are the first-line symptomatic treatment for…”
Get full text

The epidemic of methylisothiazolinone contact allergy in Europe: follow‐up on changing exposures by Uter, W., Aalto‐Korte, K., Agner, T., Andersen, K.E., Bircher, A.J., Brans, R., Bruze, M., Diepgen, T.L., Foti, C., Giménez Arnau, A., Gonçalo, M., Goossens, A., McFadden, J., Paulsen, E., Svedman, C., Rustemeyer, T., White, I.R., Wilkinson, M., Johansen, J.D.

“…Background Methylisothiazolinone (MI) has caused an unprecedented epidemic of contact allergy in Europe and elsewhere. Subsequently, regulatory action has been…”
Get full text

Pityriasis rosea developing after COVID‐19 vaccination by Marcantonio‐Santa Cruz, O.Y., Vidal‐Navarro, A., Pesqué, D., Giménez‐Arnau, A.M., Pujol, R.M., Martin‐Ezquerra, G.

Get full text

definition and diagnostic testing of physical and cholinergic urticarias - EAACI/GA²LEN/EDF/UNEV consensus panel recommendations by Magerl, M, Borzova, E, Giménez-Arnau, A, Grattan, C.E.H, Lawlor, F, Mathelier-Fusade, P, Metz, M, Młynek, A, Maurer, M

“…The recommendations for the definition and diagnosis presented in this position paper are the result of a panel consensus meeting held in December 2008 in…”
Get full text

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria by Curto‐Barredo, L., Spertino, J., Figueras‐Nart, I., Expósito‐Serrano, V., Guilabert, A., Melé‐Ninot, G., Cubiró, X., Bonfill‐Ortí, M., Garcias‐Ladaria, J., Villar, M., García‐Navarro, X., Bielsa‐Marsol, I., Vilavella, M., Aparicio, G., Baliu‐Piqué, C., Álvarez, A., Lamas‐Domenech, N., Duran‐Jordà, X., Serra‐Baldrich, E., Giménez‐Arnau, A.

Get full text

Patch test informed consent form: position statement by European Academy of Dermatology and Venereology Task Force on Contact Dermatitis by Balato, A., Scala, E., Ayala, F., Bauer, A., Crépy, M.‐N., Gonçalo, M., Duus Johansen, J., John, S.M., Rustemeyer, T., Wagner, N., Wilkinson, M., Giménez‐Arnau, A.

“…Background To our knowledge, an international consensus is lacking regarding the development of an adequate informed consent form for a patch test (PT) and the…”
Get full text

Omalizumab-Associated Steatohepatitis by Barbosa, J., Coelho, M., Brasileiro, A., Giménez-Arnau, A.

Get full text

Minimum standards on prevention, diagnosis and treatment of occupational and work‐related skin diseases in Europe – position paper of the COST Action StanDerm (TD 1206) by Alfonso, J.H., Bauer, A., Bensefa‐Colas, L., Boman, A., Bubas, M., Constandt, L., Crepy, M.N., Goncalo, M., Macan, J., Mahler, V., Mijakoski, D., Ramada Rodilla, J.M., Rustemeyer, T., Spring, P., John, S.M., Uter, W., Wilkinson, M., Giménez‐Arnau, A.M.

“…Background Skin diseases constitute up to 40% of all notified occupational diseases in most European countries, predominantly comprising contact dermatitis,…”
Get full text